Involvement of µ-opioid Receptors and κ-opioid Receptors in Itch-related Scratching Behaviour of Imiquimod-induced Psoriasis-like Dermatitis in Mice.

The pathogenesis of psoriatic itch is poorly understood. The aim of this study was to investigate the involvement of opioid receptors in scratching behaviour of imiquimod-induced psoriasis-like dermatitis model mice. Topical application of 5% imiquimod cream to the rostral back skin of mice induced antihistamine-resistant scratching behaviour. The expression of µ-opioid receptor (MOR) protein increased in the epidermis, dorsal root ganglia (DRG) and spinal cord of imiquimod-treated mice. In contrast, the expression of κ-opioid receptor (KOR) protein decreased in the DRG and spinal cord of imiquimod-treated mice, and was undetectable in the epidermis of both groups. Topical or intraperitoneal administration of the MOR antagonist naloxone and oral administration of the centrally acting KOR agonist ICI-199,441 inhibited scratching behaviour, whereas oral administration of the peri-pherally-selective KOR agonist asimadoline did not. These results suggest that peripheral and central MOR and central KOR may be involved in the modulation of scratching behaviour in imiquimod-treated mice.

[1]  G. Yosipovitch,et al.  Role of neurturin in spontaneous itch and increased nonpeptidergic intraepidermal fiber density in a mouse model of psoriasis , 2017, Pain.

[2]  T. Muramatsu,et al.  Efficacy of nalfurafine hydrochloride in patients with chronic liver disease with refractory pruritus: A randomized, double‐blind trial , 2017, Hepatology research : the official journal of the Japan Society of Hepatology.

[3]  P. Jagodziński,et al.  Opioid Receptors in Psoriatic Skin: Relationship with Itch. , 2017, Acta dermato-venereologica.

[4]  S. Ständer,et al.  Topical nalfurafine exhibits anti-inflammatory and anti-pruritic effects in a murine model of AD. , 2016, Journal of dermatological science.

[5]  S. Hirakawa,et al.  Vascular endothelial growth factor partially induces pruritus via epidermal hyperinnervation in imiquimod-induced psoriasiform dermatitis in mice. , 2016, Journal of dermatological science.

[6]  G. Yosipovitch,et al.  Mouse model of imiquimod-induced psoriatic itch , 2016, Pain.

[7]  J. Szepietowski,et al.  Pruritus in psoriasis: An update , 2016, European journal of pain.

[8]  T. Suto,et al.  Supraspinal actions of nociceptin/orphanin FQ, morphine and substance P in regulating pain and itch in non‐human primates , 2015, British journal of pharmacology.

[9]  Heeseung Lee,et al.  Distinct functions of opioid-related peptides and gastrin-releasing peptide in regulating itch and pain in the spinal cord of primates , 2015, Scientific Reports.

[10]  U. Mrowietz,et al.  Pruritus and quality of life in moderate‐to‐severe plaque psoriasis: post hoc explorative analysis from the PRISTINE study , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

[11]  S. Inui.  Nalfurafine hydrochloride to treat pruritus: a review , 2015, Clinical, cosmetic and investigational dermatology.

[12]  A. Reich,et al.  Apprehension of the disease by patients suffering from psoriasis , 2014, Postepy dermatologii i alergologii.

[13]  T. Kaneko,et al.  Dynorphin Acts as a Neuromodulator to Inhibit Itch in the Dorsal Horn of the Spinal Cord , 2014, Neuron.

[14]  K. Takamori,et al.  An update on peripheral mechanisms and treatments of itch. , 2013, Biological & pharmaceutical bulletin.

[15]  Kamal Kumar,et al.  Neuraxial opioid-induced pruritus: An update , 2013, Journal of anaesthesiology, clinical pharmacology.

[16]  D. Thakker,et al.  Cellular Mechanisms of Nociceptin/Orphanin FQ (N/OFQ) Peptide (NOP) Receptor Regulation and Heterologous Regulation by N/OFQ , 2013, Molecular Pharmacology.

[17]  S. Ständer,et al.  Systemic kappa opioid receptor agonists in the treatment of chronic pruritus: a literature review. , 2012, Acta dermato-venereologica.

[18]  Yan-Gang Sun,et al.  Unidirectional Cross-Activation of GRPR by MOR1D Uncouples Itch and Analgesia Induced by Opioids , 2011, Cell.

[19]  K. Takamori,et al.  Evaluation of epidermal nerve density and opioid receptor levels in psoriatic itch , 2011, The British journal of dermatology.

[20]  K. Takamori,et al.  Histological characterization of cutaneous nerve fibers containing gastrin-releasing peptide in NC/Nga mice: an atopic dermatitis model. , 2009, The Journal of investigative dermatology.

[21]  N. Dun,et al.  Nalfurafine prevents 5′-guanidinonaltrindole- and compound 48/80-induced spinal c-fos expression and attenuates 5′-guanidinonaltrindole-elicited scratching behavior in mice , 2009, Neuroscience.

[22]  L. Boon,et al.  Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice Is Mediated via the IL-23/IL-17 Axis1 , 2009, The Journal of Immunology.

[23]  S. Husbands,et al.  Effects of Atypical κ-Opioid Receptor Agonists on Intrathecal Morphine-Induced Itch and Analgesia in Primates , 2009, Journal of Pharmacology and Experimental Therapeutics.

[24]  J. Szepietowski,et al.  Mediators of Pruritus in Psoriasis , 2007, Mediators of inflammation.

[25]  A. Ridolfi,et al.  Pharmacokinetic aspects of naloxone‐precipitated morphine withdrawal in male and female prepubertal mice , 2007, Biopharmaceutics & drug disposition.

[26]  H. Stammer,et al.  Treatment of pruritus with topically applied opiate receptor antagonist. , 2007, Journal of the American Academy of Dermatology.

[27]  F. Rice,et al.  CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[28]  A. Cowan,et al.  Kappa opioid agonists suppress chloroquine-induced scratching in mice. , 2004, European journal of pharmacology.

[29]  C. Inturrisi.  Clinical Pharmacology of Opioids for Pain , 2002, The Clinical journal of pain.

[30]  Hiroshi Nojima,et al.  Itch-associated response induced by experimental dry skin in mice. , 2002, Japanese journal of pharmacology.

[31]  G. Fricchione,et al.  Endogenous morphine , 2000, Trends in Neurosciences.

[32]  Y. Kuraishi,et al.  Itch-Scratch Responses Induced by Opioids through Central Mu Opioid Receptors in Mice , 2000, Journal of Biomedical Science.

[33]  P. Kam,et al.  Pruritus—itching for a cause and relief? , 1996, Anaesthesia.

[34]  H. M. Bender,et al.  A pharmacological profile of the novel, peripherally‐selective k‐opioid receptor agonist, EMD 61753 , 1994, British journal of pharmacology.

[35]  J. Ballantyne,et al.  Itching after epidural and spinal opiates , 1988, Pain.

[36]  M. Piercey,et al.  Spinal and Supraspinal sites for morphine and nefopam analgesia in the mouse. , 1981, European journal of pharmacology.

[37]  M. Ko.  Neuraxial opioid-induced itch and its pharmacological antagonism. , 2015, Handbook of experimental pharmacology.

[38]  R. Thurmond,et al.  Peripheral Neuronal Mechanism of Itch , 2014 .

[39]  H. Matsuda,et al.  Recent findings in mouse models for human atopic dermatitis. , 2012, Experimental animals.

[40]  C. Gaveriaux-Ruff,et al.  Deletion of mu- and kappa-opioid receptors in mice changes epidermal hypertrophy, density of peripheral nerve endings, and itch behavior. , 2007, The Journal of investigative dermatology.

[41]  H. Nagase,et al.  Involvement of central mu-opioid system in the scratching behavior in mice, and the suppression of it by the activation of kappa-opioid system. , 2003, European journal of pharmacology.